A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer

by | Aug 3, 2026 | Clinical Trials | 0 comments

​ Conditions: Neoplasms, Rectal

Interventions: Biological: Dostarlimab

Sponsors: GlaxoSmithKline

Not yet recruiting Conditions: Neoplasms, Rectal
Interventions: Biological: Dostarlimab
Sponsors: GlaxoSmithKline
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *